Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Appella Website

Ettore Appella, M.D.

Selected Publications
1)  Bang J, Yamaguchi H, Durell SR, Appella E, Appella DH.
A small molecular scaffold for selective inhibition of Wip1 phosphatase.
ChemMedChem. 3: 230-2, 2008. [Journal]
2)  Kang T, Wei Y, Honaker Y, Yamaguchi H, Appella E, Hung MC, Piwnica-Worms H.
GSK-3 beta targets Cdc25A for ubiquitin-mediated proteolysis, and GSK-3 beta inactivation correlates with Cdc25A overproduction in human cancers.
Cancer Cell. 13: 36-47, 2008. [Journal]
3)  Lombardi M, Castoria G, Migliaccio A, Barone MV, Di Stasio R, Ciociola A, Bottero D, Yamaguchi H, Appella E, Auricchio F.
Hormone-dependent nuclear export of estradiol receptor and DNA synthesis in breast cancer cells.
J. Cell Biol. 182: 327-40, 2008. [Journal]
4)  Kumamoto K, Spillare EA, Fujita K, Horikawa I, Yamashita T, Appella E, Nagashima M, Takenoshita S, Yokota J, Harris CC.
Nutlin-3a activates p53 to both down-regulate inhibitor of growth 2 and up-regulate mir-34a, mir-34b, and mir-34c expression, and induce senescence.
Cancer Res. 68: 3193-203, 2008. [Journal]
5)  Alsheich-Bartok O, Haupt S, Alkalay-Snir I, Saito S, Appella E, Haupt Y.
PML enhances the regulation of p53 by CK1 in response to DNA damage.
Oncogene. 27: 3653-61, 2008. [Journal]
6)  Jenkins LM, Mazur SJ, Rossi M, Gaidarenko O, Xu Y, Appella E.
Quantitative proteomics analysis of the effects of ionizing radiation in wild type and p53 K317R knock-in mouse thymocytes.
Mol. Cell Proteomics. 7: 716-27, 2008. [Journal]
7)  Turpin JA, Schito ML, Jenkins LM, Inman JK, Appella E.
Topical microbicides: a promising approach for controlling the AIDS pandemic via retroviral zinc finger inhibitors.
Adv. Pharmacol. 56: 229-56, 2008. [Journal]
8)  Hu ZZ, Valencia JC, Huang H, Chi A, Shabanowitz J, Hearing VJ, Appella E, Wu C.
Comparative Bioinformatics Analyses and Profiling of Lysosome-Related Organelle Proteomes.
Int J Mass Spectrom. 259: 147-160, 2007. [Journal]
9)  Wei G, Ku S, Ma GK, Saito S, Tang AA, Zhang J, Mao JH, Appella E, Balmain A, Huang EJ.
HIPK2 represses beta-catenin-mediated transcription, epidermal stem cell expansion, and skin tumorigenesis.
Proc. Natl. Acad. Sci. U.S.A. 104: 13040-5, 2007. [Journal]
10)  Ito D, Visus C, Hoffmann TK, Balz V, Bier H, Appella E, Whiteside TL, Ferris RL, DeLeo AB.
Immunological characterization of missense mutations occurring within cytotoxic T cell-defined p53 epitopes in HLA-A*0201+ squamous cell carcinomas of the head and neck.
Int. J. Cancer. 120: 2618-24, 2007. [Journal]
11)  Varricchio L, Migliaccio A, Castoria G, Yamaguchi H, de Falco A, Di Domenico M, Giovannelli P, Farrar W, Appella E, Auricchio F.
Inhibition of estradiol receptor/Src association and cell growth by an estradiol receptor alpha tyrosine-phosphorylated peptide.
Mol. Cancer Res. 5: 1213-21, 2007. [Journal]
12)  Migliaccio A, Varricchio L, De Falco A, Castoria G, Arra C, Yamaguchi H, Ciociola A, Lombardi M, Di Stasio R, Barbieri A, Baldi A, Barone MV, Appella E, Auricchio F.
Inhibition of the SH3 domain-mediated binding of Src to the androgen receptor and its effect on tumor growth.
Oncogene. 2007. [Journal]
13)  Shi X, Kachirskaia I, Yamaguchi H, West LE, Wen H, Wang EW, Dutta S, Appella E, Gozani O.
Modulation of p53 function by SET8-mediated methylation at lysine 382.
Mol. Cell. 27: 636-46, 2007. [Journal]
14)  Appella E, Anderson CW.
New prospects for proteomics--electron-capture (ECD) and electron-transfer dissociation (ETD) fragmentation techniques and combined fractional diagonal chromatography (COFRADIC).
FEBS J. 274: 6255, 2007. [Journal]
15)  Hunt DF, Henderson RA, Shabanowitz J, Sakaguchi K, Michel H, Sevilir N, Cox AL, Appella E, Engelhard VH.
Pillars article: Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry. Science 1992. 255: 1261-1263.
J. Immunol. 179: 2669-71, 2007. [Journal]
16)  Valencia JC, Rouzaud F, Julien S, Chen KG, Passeron T, Yamaguchi Y, Abu-Asab M, Tsokos M, Costin GE, Yamaguchi H, Jenkins LM, Nagashima K, Appella E, Hearing VJ.
Sialylated core 1 O-glycans influence the sorting of Pmel17/gp100 and determine its capacity to form fibrils.
J. Biol. Chem. 282: 11266-80, 2007. [Journal]
17)  Miller PJ, Pazy Y, Conti B, Riddle D, Appella E, Collins EJ.
Single MHC mutation eliminates enthalpy associated with T cell receptor binding.
J. Mol. Biol. 373: 315-27, 2007. [Journal]
18)  Miller Jenkins LM, Hara T, Durell SR, Hayashi R, Inman JK, Piquemal JP, Gresh N, Appella E.
Specificity of acyl transfer from 2-mercaptobenzamide thioesters to the HIV-1 nucleocapsid protein.
J. Am. Chem. Soc. 129: 11067-78, 2007. [Journal]
19)  Houtman JC, Brown PH, Bowden B, Yamaguchi H, Appella E, Samelson LE, Schuck P.
Studying multisite binary and ternary protein interactions by global analysis of isothermal titration calorimetry data in SEDPHAT: application to adaptor protein complexes in cell signaling.
Protein Sci. 16: 30-42, 2007. [Journal]
20)  Demidov ON, Kek C, Shreeram S, Timofeev O, Fornace AJ, Appella E, Bulavin DV.
The role of the MKK6/p38 MAPK pathway in Wip1-dependent regulation of ErbB2-driven mammary gland tumorigenesis.
Oncogene. 26: 2502-6, 2007. [Journal]
21)  Yamaguchi H, Durell SR, Chatterjee DK, Anderson CW, Appella E.
The Wip1 phosphatase PPM1D dephosphorylates SQ/TQ motifs in checkpoint substrates phosphorylated by PI3K-like kinases.
Biochemistry. 46: 12594-603, 2007. [Journal]
22)  Sakakura K, Chikamatsu K, Furuya N, Appella E, Whiteside TL, Deleo AB.
Toward the development of multi-epitope p53 cancer vaccines: An in vitro assessment of CD8(+) T cell responses to HLA class I-restricted wild-type sequence p53 peptides.
Clin Immunol. 2007. [Journal]
23)  Demidov ON, Timofeev O, Lwin HN, Kek C, Appella E, Bulavin DV.
Wip1 phosphatase regulates p53-dependent apoptosis of stem cells and tumorigenesis in the mouse intestine.
Cell stem cell. 1: 180-90, 2007. [Journal]
24)  Chao C, Wu Z, Mazur SJ, Borges H, Rossi M, Lin T, Wang JY, Anderson CW, Appella E, Xu Y.
Acetylation of mouse p53 at lysine 317 negatively regulates p53 apoptotic activities after DNA damage.
Mol. Cell. Biol. 26: 6859-69, 2006. [Journal]
25)  Kawaguchi Y, Ito A, Appella E, Yao TP.
Charge modification at multiple C-terminal lysine residues regulates p53 oligomerization and its nucleus-cytoplasm trafficking.
J Biol Chem. 281: 1394-400, 2006. [Journal]
26)  Jenkins LM, Durell SR, Maynard AT, Stahl SJ, Inman JK, Appella E, Legault P, Omichinski JG.
Comparison of the specificity of interaction of cellular and viral zinc-binding domains with 2-mercaptobenzamide thioesters.
J. Am. Chem. Soc. 128: 11964-76, 2006. [Journal]
27)  Yamaguchi H, Durell SR, Feng H, Bai Y, Anderson CW, Appella E.
Development of a substrate-based cyclic phosphopeptide inhibitor of protein phosphatase 2Cdelta, Wip1.
Biochemistry. 45: 13193-202, 2006. [Journal]
28)  Wang LH, Yang XY, Zhang X, An P, Kim HJ, Huang J, Clarke R, Osborne CK, Inman JK, Appella E, Farrar WL.
Disruption of estrogen receptor DNA-binding domain and related intramolecular communication restores tamoxifen sensitivity in resistant breast cancer.
Cancer Cell. 10: 487-99, 2006. [Journal]
29)  Houtman JC, Yamaguchi H, Barda-Saad M, Braiman A, Bowden B, Appella E, Schuck P, Samelson LE.
Oligomerization of signaling complexes by the multipoint binding of GRB2 to both LAT and SOS1.
Nat Struct Mol Biol. 13: 798-805, 2006. [Journal]
30)  Schito ML, Soloff AC, Slovitz D, Trichel A, Inman JK, Appella E, Turpin JA, Barratt-Boyes SM.
Preclinical evaluation of a zinc finger inhibitor targeting lentivirus nucleocapsid protein in SIV-infected monkeys.
Curr HIV Res. 4: 379-86, 2006. [Journal]
31)  Chi A, Valencia JC, Hu ZZ, Watabe H, Yamaguchi H, Mangini NJ, Huang H, Canfield VA, Cheng KC, Yang F, Abe R, Yamagishi S, Shabanowitz J, Hearing VJ, Wu C, Appella E, Hunt DF.
Proteomic and bioinformatic characterization of the biogenesis and function of melanosomes.
J. Proteome Res. 5: 3135-44, 2006. [Journal]
32)  Shreeram S, Hee WK, Demidov ON, Kek C, Yamaguchi H, Fornace AJ, Anderson CW, Appella E, Bulavin DV.
Regulation of ATM/p53-dependent suppression of myc-induced lymphomas by Wip1 phosphatase.
J. Exp. Med. 203: 2793-9, 2006. [Journal]
33)  Valencia JC, Watabe H, Chi A, Rouzaud F, Chen KG, Vieira WD, Takahashi K, Yamaguchi Y, Berens W, Nagashima K, Shabanowitz J, Hunt DF, Appella E, Hearing VJ.
Sorting of Pmel17 to melanosomes through the plasma membrane by AP1 and AP2: evidence for the polarized nature of melanocytes.
J. Cell. Sci. 119: 1080-91, 2006. [Journal]
34)  Di Lello P, Jenkins LM, Jones TN, Nguyen BD, Hara T, Yamaguchi H, Dikeakos JD, Appella E, Legault P, Omichinski JG.
Structure of the Tfb1/p53 complex: Insights into the interaction between the p62/Tfb1 subunit of TFIIH and the activation domain of p53.
Mol. Cell. 22: 731-40, 2006. [Journal]
35)  Ito D, Albers A, Zhao YX, Visus C, Appella E, Whiteside TL, DeLeo AB.
The wild-type sequence (wt) p53(25-35) peptide induces HLA-DR7 and HLA-DR11-restricted CD4+ Th cells capable of enhancing the ex vivo expansion and function of anti-wt p53(264-272) peptide CD8+ T cells.
J. Immunol. 177: 6795-803, 2006. [Journal]
36)  Dudgeon C, Kek C, Demidov ON, Saito S, Fernandes K, Diot A, Bourdon JC, Lane DP, Appella E, Fornace AJ, Bulavin DV.
Tumor susceptibility and apoptosis defect in a mouse strain expressing a human p53 transgene.
Cancer Res. 66: 2928-36, 2006. [Journal]
37)  Higashimoto Y, Asanomi Y, Takakusagi S, Lewis MS, Uosaki K, Durell SR, Anderson CW, Appella E, Sakaguchi K.
Unfolding, Aggregation, and Amyloid Formation by the Tetramerization Domain from Mutant p53 Associated with Lung Cancer.
Biochemistry. 45: 1608-1619, 2006. [Journal]
38)  Shreeram S, Demidov ON, Hee WK, Yamaguchi H, Onishi N, Kek C, Timofeev ON, Dudgeon C, Fornace AJ, Anderson CW, Minami Y, Appella E, Bulavin DV.
Wip1 phosphatase modulates ATM-dependent signaling pathways.
Mol. Cell. 23: 757-64, 2006. [Journal]
39)  Schito ML, Demidov ON, Saito S, Ashwell JD, Appella E.
Wip1 phosphatase-deficient mice exhibit defective T cell maturation due to sustained p53 activation.
J. Immunol. 176: 4818-25, 2006. [Journal]
40)  Pinchuk I, Starcher BC, Livingston B, Tvninnereim A, Wu S, Appella E, Sidney J, Sette A, Wizel B.
A CD8+ T cell heptaepitope minigene vaccine induces protective immunity against Chlamydia pneumoniae.
J Immunol. 174: 5729-39, 2005. [Journal]
41)  Salvador JM, Mittelstadt PR, Guszczynski T, Copeland TD, Yamaguchi H, Appella E, Fornace AJ, Ashwell JD.
Alternative p38 activation pathway mediated by T cell receptor-proximal tyrosine kinases.
Nat Immunol. 6: 390-5, 2005. [Journal]
42)  Appella E, Anderson CW.
Identifying protein interactions.
FEBS J. 272: 5099-100, 2005. [Journal]
43)  Pedeux R, Sengupta S, Shen JC, Demidov ON, Saito S, Onogi H, Kumamoto K, Wincovitch S, Garfield SH, McMenamin M, Nagashima M, Grossman SR, Appella E, Harris CC.
ING2 regulates the onset of replicative senescence by induction of p300-dependent p53 acetylation.
Mol Cell Biol. 25: 6639-48, 2005. [Journal]
44)  Chua KF, Mostoslavsky R, Lombard DB, Pang WW, Saito S, Franco S, Kaushal D, Cheng HL, Fischer MR, Stokes N, Murphy MM, Appella E, Alt FW.
Mammalian SIRT1 limits replicative life span in response to chronic genotoxic stress.
Cell Metab. 2: 67-76, 2005. [Journal]
45)  Lin T, Chao C, Saito S, Mazur SJ, Murphy ME, Appella E, Xu Y.
p53 induces differentiation of mouse embryonic stem cells by suppressing Nanog expression.
Nat Cell Biol. 7: 165-71, 2005. [Journal]
46)  Jenkins LM, Byrd JC, Hara T, Srivastava P, Mazur SJ, Stahl SJ, Inman JK, Appella E, Omichinski JG, Legault P.
Studies on the mechanism of inactivation of the HIV-1 nucleocapsid protein NCp7 with 2-mercaptobenzamide thioesters.
J Med Chem. 48: 2847-58, 2005. [Journal]
47)  Yamaguchi H, Minopoli G, Demidov ON, Chatterjee DK, Anderson CW, Durell SR, Appella E.
Substrate specificity of the human protein phosphatase 2Cdelta, Wip1.
Biochemistry. 44: 5285-94, 2005. [Journal]
48)  Vidal B, Parra M, Jardi M, Saito S, Appella E, Munoz-Canoves P.
The alkylating carcinogen N-methyl-N'-nitro-N-nitrosoguanidine activates the plasminogen activator inhibitor-1 gene through sequential phosphorylation of p53 by ATM and ATR kinases.
Thromb Haemost. 93: 584-91, 2005. [Journal]
49)  Houtman JC, Higashimoto Y, Dimasi N, Cho S, Yamaguchi H, Bowden B, Regan C, Malchiodi EL, Mariuzza R, Schuck P, Appella E, Samelson LE.
Binding specificity of multiprotein signaling complexes is determined by both cooperative interactions and affinity preferences.
Biochemistry. 43: 4170-8, 2004. [Journal]
50)  Yasumoto K, Watabe H, Valencia JC, Kushimoto T, Kobayashi T, Appella E, Hearing VJ.
Epitope mapping of the melanosomal matrix protein gp100 (PMEL17): rapid processing in the endoplasmic reticulum and glycosylation in the early Golgi compartment.
J. Biol. Chem. 279: 28330-8, 2004. [Journal]
51)  Teruya K, Murphy AC, Burlin T, Appella E, Mazur SJ.
Fmoc-based chemical synthesis and selective binding to supercoiled DNA of the p53 C-terminal segment and its phosphorylated and acetylated derivatives.
J. Pept. Sci. 10: 479-93, 2004. [Journal]
52)  Lu X, Nguyen TA, Appella E, Donehower LA.
Homeostatic regulation of base excision repair by a p53-induced phosphatase: linking stress response pathways with DNA repair proteins.
Cell Cycle. 3: 1363-6, 2004. [Journal]
53)  Insinga A, Monestiroli S, Ronzoni S, Carbone R, Pearson M, Pruneri G, Viale G, Appella E, Pelicci P, Minucci S.
Impairment of p53 acetylation, stability and function by an oncogenic transcription factor.
EMBO J. 23: 1144-54, 2004. [Journal]
54)  Bulavin DV, Phillips C, Nannenga B, Timofeev O, Donehower LA, Anderson CW, Appella E, Fornace AJ.
Inactivation of the Wip1 phosphatase inhibits mammary tumorigenesis through p38 MAPK-mediated activation of the p16(Ink4a)-p19(Arf) pathway.
Nat. Genet. 36: 343-50, 2004. [Journal]
55)  Lu J, Higashimoto Y, Appella E, Celis E.
Multiepitope Trojan antigen peptide vaccines for the induction of antitumor CTL and Th immune responses.
J. Immunol. 172: 4575-82, 2004. [Journal]
56)  Srivastava P, Schito M, Fattah RJ, Hara T, Hartman T, Buckheit RW, Turpin JA, Inman JK, Appella E.
Optimization of unique, uncharged thioesters as inhibitors of HIV replication.
Bioorg. Med. Chem. 12: 6437-50, 2004. [Journal]
57)  Watabe H, Valencia JC, Yasumoto K, Kushimoto T, Ando H, Muller J, Vieira WD, Mizoguchi M, Appella E, Hearing VJ.
Regulation of tyrosinase processing and trafficking by organellar pH and by proteasome activity.
J. Biol. Chem. 279: 7971-81, 2004. [Journal]
58)  Wang LH, Yang XY, Zhang X, Mihalic K, Fan YX, Xiao W, Howard OM, Appella E, Maynard AT, Farrar WL.
Suppression of breast cancer by chemical modulation of vulnerable zinc fingers in estrogen receptor.
Nat. Med. 10: 40-7, 2004. [Journal]
59)  Ye R, Goodarzi AA, Kurz EU, Saito S, Higashimoto Y, Lavin MF, Appella E, Anderson CW, Lees-Miller SP.
The isoflavonoids genistein and quercetin activate different stress signaling pathways as shown by analysis of site-specific phosphorylation of ATM, p53 and histone H2AX.
DNA Repair (Amst.). 3: 235-44, 2004. [Journal]
60)  Lu X, Bocangel D, Nannenga B, Yamaguchi H, Appella E, Donehower LA.
The p53-induced oncogenic phosphatase PPM1D interacts with uracil DNA glycosylase and suppresses base excision repair.
Mol. Cell. 15: 621-34, 2004. [Journal]
61)  Buslepp J, Wang H, Biddison WE, Appella E, Collins EJ.
A correlation between TCR Valpha docking on MHC and CD8 dependence: implications for T cell selection.
Immunity. 19: 595-606, 2003. [Journal]
62)  Chao C, Hergenhahn M, Kaeser MD, Wu Z, Saito S, Iggo R, Hollstein M, Appella E, Xu Y.
Cell type- and promoter-specific roles of Ser18 phosphorylation in regulating p53 responses.
J. Biol. Chem. 278: 41028-33, 2003. [Journal]
63)  Knights CD, Liu Y, Appella E, Kulesz-Martin M.
Defective p53 post-translational modification required for wild type p53 inactivation in malignant epithelial cells with mdm2 gene amplification.
J. Biol. Chem. 278: 52890-900, 2003. [Journal]
64)  Cheng HL, Mostoslavsky R, Saito S, Manis JP, Gu Y, Patel P, Bronson R, Appella E, Alt FW, Chua KF.
Developmental defects and p53 hyperacetylation in Sir2 homolog (SIRT1)-deficient mice.
Proc. Natl. Acad. Sci. U.S.A. 100: 10794-9, 2003. [Journal]
65)  Bulavin DV, Higashimoto Y, Demidenko ZN, Meek S, Graves P, Phillips C, Zhao H, Moody SA, Appella E, Piwnica-Worms H, Fornace AJ.
Dual phosphorylation controls Cdc25 phosphatases and mitotic entry.
Nat. Cell Biol. 5: 545-51, 2003. [Journal]
66)  Buslepp J, Kerry SE, Loftus D, Frelinger JA, Appella E, Collins EJ.
High affinity xenoreactive TCR:MHC interaction recruits CD8 in absence of binding to MHC.
J. Immunol. 170: 373-83, 2003. [Journal]
67)  Yoshida A, Urasaki Y, Waltham M, Bergman AC, Pourquier P, Rothwell DG, Inuzuka M, Weinstein JN, Ueda T, Appella E, Hickson ID, Pommier Y.
Human apurinic/apyrimidinic endonuclease (Ape1) and its N-terminal truncated form (AN34) are involved in DNA fragmentation during apoptosis.
J. Biol. Chem. 278: 37768-76, 2003. [Journal]
68)  Doolan DL, Southwood S, Freilich DA, Sidney J, Graber NL, Shatney L, Bebris L, Florens L, Dobano C, Witney AA, Appella E, Hoffman SL, Yates JR, Carucci DJ, Sette A.
Identification of Plasmodium falciparum antigens by antigenic analysis of genomic and proteomic data.
Proc. Natl. Acad. Sci. U.S.A. 100: 9952-7, 2003. [Journal]
69)  Schito ML, Goel A, Song Y, Inman JK, Fattah RJ, Rice WG, Turpin JA, Sher A, Appella E.
In vivo antiviral activity of novel human immunodeficiency virus type 1 nucleocapsid p7 zinc finger inhibitors in a transgenic murine model.
AIDS Res. Hum. Retroviruses. 19: 91-101, 2003. [Journal]
70)  Hofseth LJ, Saito S, Hussain SP, Espey MG, Miranda KM, Araki Y, Jhappan C, Higashimoto Y, He P, Linke SP, Quezado MM, Zurer I, Rotter V, Wink DA, Appella E, Harris CC.
Nitric oxide-induced cellular stress and p53 activation in chronic inflammation.
Proc. Natl. Acad. Sci. U.S.A. 100: 143-8, 2003. [Journal]
71)  Shiseki M, Nagashima M, Pedeux RM, Kitahama-Shiseki M, Miura K, Okamura S, Onogi H, Higashimoto Y, Appella E, Yokota J, Harris CC.
p29ING4 and p28ING5 bind to p53 and p300, and enhance p53 activity.
Cancer Res. 63: 2373-8, 2003. [Journal]
72)  Chikamatsu K, Albers A, Stanson J, Kwok WW, Appella E, Whiteside TL, DeLeo AB.
P53(110-124)-specific human CD4+ T-helper cells enhance in vitro generation and antitumor function of tumor-reactive CD8+ T cells.
Cancer Res. 63: 3675-81, 2003. [Journal]
73)  Saito S, Yamaguchi H, Higashimoto Y, Chao C, Xu Y, Fornace AJ, Appella E, Anderson CW.
Phosphorylation site interdependence of human p53 post-translational modifications in response to stress.
J. Biol. Chem. 278: 37536-44, 2003. [Journal]
74)  Basrur V, Yang F, Kushimoto T, Higashimoto Y, Yasumoto K, Valencia J, Muller J, Vieira WD, Watabe H, Shabanowitz J, Hearing VJ, Hunt DF, Appella E.
Proteomic analysis of early melanosomes: identification of novel melanosomal proteins.
J. Proteome Res. 2: 69-79, 2003. [Journal]
75)  Goloudina A, Yamaguchi H, Chervyakova DB, Appella E, Fornace AJ, Bulavin DV.
Regulation of human Cdc25A stability by Serine 75 phosphorylation is not sufficient to activate a S phase checkpoint.
Cell Cycle. 2: 473-8, 2003. [Journal]
76)  Livingston B, Crimi C, Newman M, Higashimoto Y, Appella E, Sidney J, Sette A.
A rational strategy to design multiepitope immunogens based on multiple Th lymphocyte epitopes.
J. Immunol. 168: 5499-506, 2002. [Journal]
77)  Bulavin DV, Demidov ON, Saito S, Kauraniemi P, Phillips C, Amundson SA, Ambrosino C, Sauter G, Nebreda AR, Anderson CW, Kallioniemi A, Fornace AJ, Appella E.
Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity.
Nat. Genet. 31: 210-5, 2002. [Journal]
78)  Saito S, Goodarzi AA, Higashimoto Y, Noda Y, Lees-Miller SP, Appella E, Anderson CW.
ATM mediates phosphorylation at multiple p53 sites, including Ser(46), in response to ionizing radiation.
J. Biol. Chem. 277: 12491-4, 2002. [Journal]
79)  Goel A, Mazur SJ, Fattah RJ, Hartman TL, Turpin JA, Huang M, Rice WG, Appella E, Inman JK.
Benzamide-based thiolcarbamates: a new class of HIV-1 NCp7 inhibitors.
Bioorg. Med. Chem. Lett. 12: 767-70, 2002. [Journal]
80)  Takai H, Naka K, Okada Y, Watanabe M, Harada N, Saito S, Anderson CW, Appella E, Nakanishi M, Suzuki H, Nagashima K, Sawa H, Ikeda K, Motoyama N.
Chk2-deficient mice exhibit radioresistance and defective p53-mediated transcription.
EMBO J. 21: 5195-205, 2002. [Journal]
81)  Horikawa I, Cable PL, Mazur SJ, Appella E, Afshari CA, Barrett JC.
Downstream E-box-mediated regulation of the human telomerase reverse transcriptase (hTERT) gene transcription: evidence for an endogenous mechanism of transcriptional repression.
Mol. Biol. Cell. 13: 2585-97, 2002. [Journal]
82)  Hoffmann TK, Donnenberg AD, Finkelstein SD, Donnenberg VS, Friebe-Hoffmann U, Myers EN, Appella E, DeLeo AB, Whiteside TL.
Frequencies of tetramer+ T cells specific for the wild-type sequence p53(264-272) peptide in the circulation of patients with head and neck cancer.
Cancer Res. 62: 3521-9, 2002. [Journal]
83)  Kuwata T, Gongora C, Kanno Y, Sakaguchi K, Tamura T, Kanno T, Basrur V, Martinez R, Appella E, Golub T, Ozato K.
Gamma interferon triggers interaction between ICSBP (IRF-8) and TEL, recruiting the histone deacetylase HDAC3 to the interferon-responsive element.
Mol. Cell. Biol. 22: 7439-48, 2002. [Journal]
84)  D'Orazi G, Cecchinelli B, Bruno T, Manni I, Higashimoto Y, Saito S, Gostissa M, Coen S, Marchetti A, Del Sal G, Piaggio G, Fanciulli M, Appella E, Soddu S.
Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis.
Nat. Cell Biol. 4: 11-9, 2002. [Journal]
85)  Ito A, Kawaguchi Y, Lai CH, Kovacs JJ, Higashimoto Y, Appella E, Yao TP.
MDM2-HDAC1-mediated deacetylation of p53 is required for its degradation.
EMBO J. 21: 6236-45, 2002. [Journal]
86)  Choi J, Nannenga B, Demidov ON, Bulavin DV, Cooney A, Brayton C, Zhang Y, Mbawuike IN, Bradley A, Appella E, Donehower LA.
Mice deficient for the wild-type p53-induced phosphatase gene (Wip1) exhibit defects in reproductive organs, immune function, and cell cycle control.
Mol. Cell. Biol. 22: 1094-105, 2002. [Journal]
87)  Wizel B, Starcher BC, Samten B, Chroneos Z, Barnes PF, Dzuris J, Higashimoto Y, Appella E, Sette A.
Multiple Chlamydia pneumoniae antigens prime CD8+ Tc1 responses that inhibit intracellular growth of this vacuolar pathogen.
J. Immunol. 169: 2524-35, 2002. [Journal]
88)  Wu Z, Earle J, Saito S, Anderson CW, Appella E, Xu Y.
Mutation of mouse p53 Ser23 and the response to DNA damage.
Mol. Cell. Biol. 22: 2441-9, 2002. [Journal]
89)  Song Y, Goel A, Basrur V, Roberts PE, Mikovits JA, Inman JK, Turpin JA, Rice WG, Appella E.
Synthesis and biological properties of amino acid amide ligand-based pyridinioalkanoyl thioesters as anti-HIV agents.
Bioorg. Med. Chem. 10: 1263-73, 2002. [Journal]
90)  Hoffmann TK, Loftus DJ, Nakano K, Maeurer MJ, Chikamatsu K, Appella E, Whiteside TL, DeLeo AB.
The ability of variant peptides to reverse the nonresponsiveness of T lymphocytes to the wild-type sequence p53(264-272) epitope.
J. Immunol. 168: 1338-47, 2002. [Journal]
91)  Mauser A, Saito S, Appella E, Anderson CW, Seaman WT, Kenney S.
The Epstein-Barr virus immediate-early protein BZLF1 regulates p53 function through multiple mechanisms.
J. Virol. 76: 12503-12, 2002. [Journal]
92)  Yang Q, Zhang R, Wang XW, Spillare EA, Linke SP, Subramanian D, Griffith JD, Li JL, Hickson ID, Shen JC, Loeb LA, Mazur SJ, Appella E, Brosh RM, Karmakar P, Bohr VA, Harris CC.
The processing of Holliday junctions by BLM and WRN helicases is regulated by p53.
J. Biol. Chem. 277: 31980-7, 2002. [Journal]
93)  Kushimoto T, Basrur V, Valencia J, Matsunaga J, Vieira WD, Ferrans VJ, Muller J, Appella E, Hearing VJ.
A model for melanosome biogenesis based on the purification and analysis of early melanosomes.
Proc. Natl. Acad. Sci. U.S.A. 98: 10698-703, 2001. [Journal]
94)  Wilson CC, Palmer B, Southwood S, Sidney J, Higashimoto Y, Appella E, Chesnut R, Sette A, Livingston BD.
Identification and antigenicity of broadly cross-reactive and conserved human immunodeficiency virus type 1-derived helper T-lymphocyte epitopes.
J. Virol. 75: 4195-207, 2001. [Journal]
95)  Bulavin DV, Higashimoto Y, Popoff IJ, Gaarde WA, Basrur V, Potapova O, Appella E, Fornace AJ.
Initiation of a G2/M checkpoint after ultraviolet radiation requires p38 kinase.
Nature. 411: 102-7, 2001. [Journal]
96)  Appella E, Fox JW, Anderson CW.
Meeting report. Methods in Protein Structural Analysis Conference (MPSA2000), Charlottesville, Virginia, September 16-20, 2000.
Protein Sci. 10: 459-61, 2001. [Journal]
97)  Appella E.
Modulation of p53 function in cellular regulation.
Eur. J. Biochem. 268: 2763, 2001. [Journal]
98)  Ito A, Lai CH, Zhao X, Saito S, Hamilton MH, Appella E, Yao TP.
p300/CBP-mediated p53 acetylation is commonly induced by p53-activating agents and inhibited by MDM2.
EMBO J. 20: 1331-40, 2001. [Journal]
99)  Appella E, Anderson CW.
Post-translational modifications and activation of p53 by genotoxic stresses.
Eur. J. Biochem. 268: 2764-72, 2001. [Journal]
100)  Buslepp J, Zhao R, Donnini D, Loftus D, Saad M, Appella E, Collins EJ.
T cell activity correlates with oligomeric peptide-major histocompatibility complex binding on T cell surface.
J. Biol. Chem. 276: 47320-8, 2001. [Journal]
101)  Lu J, Wettstein PJ, Higashimoto Y, Appella E, Celis E.
TAP-independent presentation of CTL epitopes by Trojan antigens.
J. Immunol. 166: 7063-71, 2001. [Journal]
102)  Kobayashi H, Song Y, Hoon DS, Appella E, Celis E.
Tumor-reactive T helper lymphocytes recognize a promiscuous MAGE-A3 epitope presented by various major histocompatibility complex class II alleles.
Cancer Res. 61: 4773-8, 2001. [Journal]
103)  Appella E, Appella D, Durell S, Bang J, Yamaguchi H, inventor; DHHS, assignee.
A Family of Small Molecules for Selective Inhibition of Wip 1 Phosphatase.
Patent Pending, Filed in 2008. Application No. 60/969,258. Pending [Patent]
104)  Appella E, Goel A, Inman J, Schito M, Turpin J, inventor; DHHS, assignee.
Acylthiols And Component Thiol Compositions As Anti-hiv And Anti-Retroviral Agents.
Patent Pending, Filed in 2000. Application No. 10/485,165. Pending [Patent]
105)  Bulavin D, Appella E, Fornace A, Kallioniemi A, inventor; DHHS, assignee.
Materials And Methods For Inhibiting Wip-1.
Patent Pending, Filed in 2002. Application No. 11/868,794. Pending [Patent]
106)  Matsushima K, Yoshimura T, Leonard E, Oppenheim J, Appella E, Showalter S, inventor; DHHS, assignee.
Antibodies Specific for Neutrophil Chemotactic Factor.
US Patent: 5,698,196. 1997. [Patent]
107)  DeLeo A, Loftus D, Appella E, inventor; DHHS, assignee.
cDNA clone for tumor rejection antigen gp110 and tumor peptide vaccine.
US Patent: 6,514,493. 2003. [Patent]
108)  Yoshimura T, Robinson E, Appella E, Leonard E, inventor; DHHS, assignee.
Human derived monocyte attracting purified peptide products useful in a method of treating infection and neoplasms in a human body.
US Patent: 6,090,795. 2000. [Patent]
109)  Yoshimura T, Robinson E, Appella E, Leonard E, inventor; DHHS, assignee.
Human Derived Monocyte Attracting Purified Protein Product Useful in a Method of Treating Infection and Neoplasms in a Human Body.
US Patent: 5,714,578. 1998. [Patent]
110)  Yoshimura T, Robinson E, Appella E, Leonard E, inventor; DHHS, assignee.
Human derived monocyte attracting purified protein product useful in a method of treating infection and neoplasms in a human body, and the cloning of full length cDNA thereof.
US Patent: 6,869,924. 2005. [Patent]
111)  Leonard E, Skeel A, Yoshimura T, Appella E, inventor; DHHS, assignee.
Macrophage-stimulating Protein.
US Patent: 5,219,991. 1993. [Patent]
112)  Anderson C, Appella E, Sakaguchi K, inventor; DHHS, assignee.
Method For Generating Phosphorylation Site-specific Immunologic Reagents.
US Patent: 6,309,863. 2001. [Patent]
113)  Matsushima K, Yoshimura T, Leonard E, Oppenheim J, Appella E, Showalter S, inventor; DHHS, assignee.
Method of treating inflammation with antibodies to neutrophil chemotactic factor.
US Patent: 5,925,352. 1999. [Patent]
114)  Matsushima K, Yoshimura T, Leonard E, Oppenheim J, Appella E, Showalter S, inventor; DHHS, assignee.
Neutrophil Chemotactic Factor.
US Patent: 5,652,338. 1997. [Patent]
115)  Matsushima K, Yoshimura T, Leonard E, Oppenheim J, Appella E, Showalter S, inventor; DHHS, assignee.
Neutrophil chemotactic factor cloned cDNA and monoclonal antibodies thereto.
US Patent: 6,475,741. 2002. [Patent]
116)  Matsushima K, Yoshimura T, Leonard E, Oppenheim J, Appella E, Showalter S, inventor; DHHS, assignee.
Nucleic acids encoding a novel neutrophil chemotactic factor.
US Patent: 6,376,659. 2002. [Patent]
117)  Yoshimura T, Robinson E, Appella E, Leonard E, inventor; DHHS, assignee.
Process for Preparing Human-derived Monocyte Attracting Purified Peptide Products Useful in a Method of Treating Infection and Neoplasms in a Human Body.
US Patent: 5,532,144. 1996. [Patent]
118)  Turpin J, Song Y, Appella E, Inman J, Covell D, Rice W, Wallqvist A, Maynard A, Huang M, inventor; DHHS, assignee.
Thiolesters and uses thereof.
US Patent: 6,706,729. 2004. [Patent]
119)  Dano K, Blasi F, Roldan A, Cubellis M, Masucci M, Appella E, Schleuning W, Behrendt N, Ronne E, Kristensen P, Pollanen J, Salonen E, Stephens R, Tapiovaara H, Vaheri A, Moller L, Ellis V, Lund L, Ploug M, Pyke C, Patthy L, inventor; DHHS, assignee.
Vectors and methods for recombinant production of uPA-binding fragments of the human urokinase-type plasminogen receptor (uPAR).
US Patent: 5,891,664. 1999. [Patent]

This page was last updated on 11/20/2008.